Course

The Biologic Revolution in Systemic Lupus Erythematosus

We’ll take a look at how the treatment landscape in SLE is evolving, why the development of new therapies has historically been so frustrating, and how new breakthroughs are giving hope to the latest generation of patients with SLE.

0 out of 5 steps completed0%
0 Lessons

The Biologic Revolution in Systemic Lupus Erythematosus: Why it Matters to Our Patients

PROVIDED BY:

Support for this activity has been made possible through an educational grant from GSK

TARGET AUDIENCE

This activity has been designed to meet the educational needs of nurses and nurse practitioners. Other healthcare providers may also participate.

ACTIVITY DESCRIPTION

In this issue of Rheumatology Nurse Practice, we’ll take a look at how the treatment landscape in SLE is evolving, why the development of new therapies has historically been so frustrating, and how new breakthroughs are giving hope to the latest generation of patients with SLE.

LEARNING OBJECTIVES

After participating in the activity, learners should be better able to:

  • Discuss the evidence supporting and limiting the use of traditional mainstay therapies for the treatment of SLE
  • Identify the most common and significant side effects associated with traditional therapies used to treat SLE
  • Assess the appropriate utilization of biologic therapies among patients with SLE being treated in your practice
  • Analyze the potential utility of new therapies under late-stage investigation for the treatment of SLE

DISCLOSURE STATEMENT

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

RELATIONSHIPS ARE ABBREVIATED AS FOLLOWS:

E: Educational planning committee
G: Grant/research support recipient
A: Advisor/review panel member
C: Consultant
S: Stock shareholder
SB: Speaker bureau
PE: Promotional event talks
H: Honoraria
O: Other

DISCLOSURES AS FOLLOWS:

Linda Grinnell-Merrick, MS, NP-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Celgene, Janssen, Novartis/SB; Lilly, Sanofi-Aventis/C.

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Crescendo Biosciences, Horizon/SB; Pfizer/C.

Monica Richey, MSN, ANP-CP/GNP, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Mallinckrodt/A.

Jacqueline Fritz, RN, MSN, CNS, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Lilly, AbbVie, Celgene, Horizon, Momenta Pharmaceuticals/A; Celgene, AbbVie, Genentech, Horizon/SB.

INDEPENDENT CLINICAL PEER REVIEWER

This newsletter was reviewed by Tiffany Clark, CNP. Ms. Clark has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

PLANNING COMMITTEE

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner, Rheumatology Nurses Society, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Scott Kober, MBA, President, MedCaseWriter, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

Kathy Holliman, MEd, Medical Writer, has disclosed that she does not have any relevant financial relationships specific to the subject matter of the content of the activity.
Kevin D. Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC, has disclosed that he does not have any relevant financial relationships specific to the subject matter of the content of the activity.

OFF-LABEL PRODUCT DISCLOSURE

There will be no discussion of investigational and/or off-label use of pharmaceutical products or devices within this activity.

ACCREDITATION AND CREDIT DESIGNATION

Nurses

Rheumatology Nurses Society is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Rheumatology Nurses Society designates this educational activity for 2.5 contact hours (2.5 pharmacotherapeutic contact hours).

METHOD OF PARTICIPATION

There are no fees to participate in the activity. Participants must review the activity information, including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE credit for your participation, please go to rnsnurse.com/rnpce and complete the post-test (achieving a passing grade of 70% or greater) and program evaluation. Your certificate will be emailed to you upon completion.

COPYRIGHT

© 2018. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).